CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 170 enrolled
Drug / intervention
Ascorbic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02106975
NCT02106975Phase 2Completed

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

Virginia Commonwealth University·interventional·Posted Apr 8, 2014·Updated Oct 15, 2019

In Brief

A Phase 2 clinical trial evaluating Ascorbic Acid and Placebo: 5% Dextrose in water for Acute Lung Injury and Sepsis. Completed, enrolled 170 participants across 5 sites.

Detailed Summary

Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartApr 1, 2014
Primary CompletionNov 16, 2017
Study CompletionJan 8, 2018
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.2 years ago

Interventions

Ascorbic Aciddrug

Intervention

Placebo: 5% Dextrose in waterdrug

Placebo